CN113784968B - Wee1抑制剂化合物的晶型及其应用 - Google Patents
Wee1抑制剂化合物的晶型及其应用 Download PDFInfo
- Publication number
- CN113784968B CN113784968B CN202080031816.4A CN202080031816A CN113784968B CN 113784968 B CN113784968 B CN 113784968B CN 202080031816 A CN202080031816 A CN 202080031816A CN 113784968 B CN113784968 B CN 113784968B
- Authority
- CN
- China
- Prior art keywords
- crystal form
- form according
- pattern
- whose
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| CN201910364694X | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113784968A CN113784968A (zh) | 2021-12-10 |
| CN113784968B true CN113784968B (zh) | 2024-03-15 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080031816.4A Active CN113784968B (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (enExample) |
| EP (1) | EP3964510B1 (enExample) |
| JP (1) | JP7582970B2 (enExample) |
| CN (1) | CN113784968B (enExample) |
| AU (1) | AU2020266956B2 (enExample) |
| BR (1) | BR112021021230A8 (enExample) |
| CA (1) | CA3138240C (enExample) |
| DK (1) | DK3964510T3 (enExample) |
| ES (1) | ES2984617T3 (enExample) |
| FI (1) | FI3964510T3 (enExample) |
| HR (1) | HRP20241008T1 (enExample) |
| HU (1) | HUE068061T2 (enExample) |
| IL (1) | IL287472A (enExample) |
| LT (1) | LT3964510T (enExample) |
| PL (1) | PL3964510T3 (enExample) |
| PT (1) | PT3964510T (enExample) |
| RS (1) | RS65747B1 (enExample) |
| SG (1) | SG11202111315XA (enExample) |
| SI (1) | SI3964510T1 (enExample) |
| SM (1) | SMT202400303T1 (enExample) |
| WO (1) | WO2020221358A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623615A (zh) * | 2017-03-23 | 2018-10-09 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| NZ598071A (en) * | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| EP2155752B1 (en) * | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| PL2477628T3 (pl) | 2009-09-15 | 2015-02-27 | Merck Sharp & Dohme | Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| EP2731953A1 (en) | 2011-07-15 | 2014-05-21 | Abbvie Inc. | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA3003737C (en) | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| JP7290638B2 (ja) | 2017-11-01 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としての大環状化合物及びその使用 |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
-
2020
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623615A (zh) * | 2017-03-23 | 2018-10-09 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12291536B2 (en) | 2025-05-06 |
| PL3964510T3 (pl) | 2024-08-19 |
| CA3138240A1 (en) | 2020-11-05 |
| AU2020266956A1 (en) | 2021-10-28 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| PT3964510T (pt) | 2024-07-29 |
| DK3964510T3 (da) | 2024-07-29 |
| ES2984617T3 (es) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| EP3964510A4 (en) | 2023-04-26 |
| SG11202111315XA (en) | 2021-11-29 |
| IL287472A (en) | 2021-12-01 |
| LT3964510T (lt) | 2024-08-12 |
| SMT202400303T1 (it) | 2024-09-16 |
| HRP20241008T1 (hr) | 2024-11-08 |
| RS65747B1 (sr) | 2024-08-30 |
| FI3964510T3 (fi) | 2024-07-24 |
| JP7582970B2 (ja) | 2024-11-13 |
| BR112021021230A2 (enExample) | 2021-12-21 |
| EP3964510A1 (en) | 2022-03-09 |
| US20220220120A1 (en) | 2022-07-14 |
| EP3964510B1 (en) | 2024-07-03 |
| CN113784968A (zh) | 2021-12-10 |
| SI3964510T1 (sl) | 2024-10-30 |
| CA3138240C (en) | 2025-04-01 |
| WO2020221358A1 (zh) | 2020-11-05 |
| AU2020266956B2 (en) | 2025-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113784968B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
| CN114728957B (zh) | 一种atr抑制剂的晶型及其应用 | |
| CN114026104B (zh) | Cot调节剂及其使用方法 | |
| EP4640689A1 (en) | Crystal form of kras g12d inhibitor and preparation method therefor | |
| Gu et al. | Synthesis, cytotoxic evaluation and DNA binding study of 9-fluoro-6 H-indolo [2, 3-b] quinoxaline derivatives | |
| KR20130122612A (ko) | 오에스아이 906의 다형체 | |
| US20210101881A1 (en) | Pyrimidine compound, preparation method thereof and medical use thereof | |
| CN109053592B (zh) | 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
| EP3511333B1 (en) | Crystal form and salt form of 7h-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor | |
| EP3896063A1 (en) | Salt of syk inhibitor and crystalline form thereof | |
| US11040952B2 (en) | Phthalazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof | |
| CN110467637B (zh) | 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用 | |
| CN117355528B (zh) | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 | |
| HK40060045A (en) | Crystal form of wee1 inhibitor compound and use thereof | |
| RU2842334C2 (ru) | Кристаллическая форма ингибирующего wee1 соединения и ее применение | |
| CN113825760B (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
| CN112585120B (zh) | 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法 | |
| CN111606888B (zh) | 吡咯类衍生物及其制备方法与应用 | |
| HK40060045B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
| CN110590663A (zh) | 一种1，8-萘酰亚胺衍生物及其应用 | |
| CN107459494B (zh) | 苯并吗啉酮衍生物及其制备方法和用途 | |
| HK40074313B (zh) | 一种atr抑制剂的晶型及其应用 | |
| HK40039872A (en) | Angiotensin ii receptor 2 antagonist salt form and crystalline form, and preparation method therefor | |
| CN118598874A (zh) | 一种取代的9h嘌呤类化合物、药物组合物及其用途 | |
| CN119431319A (zh) | 环戊基并吡啶衍生物的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220121 Address after: 214000 room 315, No. 88, Meishan Meiliang Road, Binhu District, Wuxi City, Jiangsu Province Applicant after: Wuxi Zhikang Hongyi Biotechnology Co.,Ltd. Address before: 050035 16th floor, innovation building, No. 315, Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Applicant before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060045 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |